PDCD1 and neoplasm: Currently, to provide additional synergy for improving the outcome of blocking PD-L1/PD-1 interaction, the Shen’s group utilized IR-LND- or MHI148-modified bovine serum albumin in conjunction with the multi-kinase inhibitor sorafenib to show significantly increased oxygen perfusion in tumor cells.